Key clinical point: A dose of 100 mg guselkumab every 4/8 weeks (Q4W/Q8W) demonstrated a rapid and sustained improvement in different disease activity (DA) domains in patients with psoriatic arthritis (PsA).
Major finding: Significantly higher proportion of patients receiving guselkumab Q4W/Q8W vs placebo achieved low DA in PsA (DAPSA) at week 8 (19.8%/17.3% vs 8.1%), DAPSA remission at week 12 (4.3%/4.3% vs 0.5%), minimal DA at week 16 (14.7%/16.5% vs 4.6%; all P < .001,) and very low DA at week 24 (6.4%/4.3% vs 1.3%; P < .05), with improvements maintained till week 52.
Study details: Findings are from a pooled analysis of 2 phase 3 trials ( DISCOVER-1 and DISCOVER-2) including 1120 patients with active PsA who had inadequate response to standard therapies or were biologic-naive and were randomly assigned to receive 100 mg guselkumab (Q4W/Q8W) or placebo.
Disclosures: This study was funded by Janssen Research & Development, LLC. Eight authors reported being current or former employees of Janssen and stockholders of Johnson & Johnson, the parent company of Janssen. The other authors reported ties with various sources, including Janssen.
Source: Coates LC et al. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford). 2022 (Jun 29). Doi: 10.1093/rheumatology/keac375